



(12) Translation of
European patent specification

(11) NO/EP 2854814 B1

NORWAY


(19) NO
(51) Int Cl.
A61K 31/5377 (2006.01)
A61P 25/24 (2006.01)
C07D 471/04 (2006.01)

Norwegian Industrial Property Office

(21)	Translation Published	2018.06.25
(80)	Date of The European Patent Office Publication of the Granted Patent	2018.01.31
(86)	European Application Nr.	13793417.0
(86)	European Filing Date	2013.05.24
(87)	The European Application's Publication Date	2015.04.08
(30)	Priority	2012.05.25, US, 201261651669 P 2012.08.20, US, 201261691083 P 2012.10.19, US, 201261715907 P 2013.02.01, US, 201361759520 P 2013.03.14, US, 201361781629 P
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
(73)	Proprietor	Corcept Therapeutics, Inc., 149 Commonwealth Drive, Menlo Park CA 94025, US-USA
(72)	Inventor	HUNT, Hazel, Edenderry HouseBracken Close, Storrington West Sussex, GB-Storbritannia JOHNSON, Tony, 8/9 Spire Green CentreFlex Meadow, Harlow Essex, GB-Storbritannia RAY, Nicholas, 8/9 Spire Green CentreFlex Meadow, Harlow Essex, GB-Storbritannia WALTERS, Iain, BioCityPennyfoot Street, Nottingham NG1 1GF, GB-Storbritannia
(74)	Agent or Attorney	ZACCO NORWAY AS, Postboks 2003 Vika, 0125 OSLO, Norge

(54)	Title	HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS
(56)	References Cited:	WO-A1-2005/087769, WO-A1-2012/027702, US-A1- 2011 166 110, US-A1- 2007 281 928, US-A1- 2010 179 115, US-A- 4 963 558

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

PATENTKRAV**1.** Forbindelse som har formelen:

5

hvor

R^1 er en heteroarylring som har fra 5 til 6 ringmedlemmer og fra 1 til 4 heteroatomer hver uafhængig valgt fra gruppen som består af N, O og S, eventuelt substitueret med 1-4 grupper hver uafhængig valgt fra R_{1a} ;

hver R^{1a} er uafhængig valgt fra gruppen som består af hydrogen, C_{1-6} alkyl, halogen, C_{1-6} haloalkyl, C_{1-6} alkoksy, C_{1-6} haloalkoksy, -CN, N-oxid, C_{3-8} sykloalkyl, og C_{3-8} heterosykloalkyl;

ring J er valgt fra gruppen som består af en sykloalkylring, en heterosykloalkylring, en arylring og en heteroarylring, hvori heterosykloalkyl- og heteroarylringene har fra 5 til 6 ringmedlemmer og fra 1 til 4 heteroatomer hver uafhængig valgt fra gruppen som består af N, O og S;

hver R^2 er uafhængig valgt fra gruppen som består af hydrogen, C_{1-6} alkyl, halogen, C_{1-6} haloalkyl, C_{1-6} alkoksy, C_{1-6} haloalkoksy, C_{1-6} alkyl- C_{1-6} alkoksy, -CN, -OH, $-NR^{2a}R^{2b}$, $-C(O)R^{2a}$, $-C(O)OR^{2a}$, $-C(O)NR^{2a}R^{2b}$, $-SR^{2a}$, $-S(O)R^{2a}$, $-S(O)_2R^{2a}$, C_{3-8} sykloalkyl, og C_{3-8} heterosykloalkyl, hvori heterosykloalkylgruppene eventuelt er substitueret med 1-4 R^{2c} -grupper;

alternativt kombineres to R^2 -grupper knyttet til samme karbon for at danne en oksogruppe (=O);

alternativt kombineres to R^2 -grupper for at danne en heterosykloalkylring som har fra 5 til 6 ringmedlemmer og fra 1 til 3 heteroatomer hver uafhængig valgt fra gruppen som består af N, O og S, hvori heterosykloalkylringen eventuelt er substitueret med fra 1 til 3 R^{2d} -grupper;

R^{2a} og R^{2b} er hver uafhængig valgt fra gruppen som består af hydrogen og C_{1-6} alkyl;

30

hver R^{2c} er uavhengig valgt fra gruppen som består av hydrogen, halogen, hydroksy, C_{1-6} alkoksy, C_{1-6} haloalkoksy, -CN, og $-NR^{2a}R^{2b}$;

hver R^{2d} er uavhengig valgt fra gruppen som består av hydrogen og C_{1-6} alkyl, eller to R^{2d} -grupper knyttet til det samme ringatomet kombineres for å danne
5 (=O);

R^3 er valgt fra gruppen som består av fenyl og pyridyl, hver eventuelt substituert med 1-4 R^{3a} -grupper;

hver R^{3a} er uavhengig valgt fra gruppen som består av hydrogen, halogen og C_{1-6} haloalkyl;

10 den senkede skriften n er et heltall fra 0 til 3;
eller salter derav.

2. Forbindelsen ifølge krav 1, hvori

R^1 er en heteroarylring som har fra 5 til 6 ringmedlemmer og fra 1 til 4
15 heteroatomer hver uavhengig valgt fra gruppen som består av N, O og S, eventuelt substituert med 1-4 grupper hver uavhengig valgt fra R^{1a} ;

hver R^{1a} er uavhengig valgt fra gruppen som består av hydrogen, C_{1-6} alkyl, halogen, C_{1-6} haloalkyl, C_{1-6} alkoksy, C_{1-6} haloalkoksy, -CN, C_{3-8} sykloalkyl, og C_{3-8} heterosykloalkyl;

20 ring J velges fra gruppen som består av en sykloalkylring, en heterosykloalkylring, en arylring og en heteroarylring, hvori heterosykloalkyl- og heteroarylringene har fra 5 til 6 ringmedlemmer og fra 1 til 3 heteroatomer hver uavhengig valgt gruppen som består av N, O og S;

hver R^2 er uavhengig valgt fra gruppen som består av hydrogen, C_{1-6} alkyl, halogen, C_{1-6} haloalkyl, C_{1-6} alkoksy, C_{1-6} haloalkoksy, -CN, $NR^{2a}R^{2b}$, C_{3-8} sykloalkyl, og C_{3-8} heterosykloalkyl, hvori heterosykloalkylgruppene eventuelt er substituert med 1-4 R^{2c} -grupper;

R^{2a} og R^{2b} er hver uavhengig valgt fra gruppen som består av hydrogen og C_{1-6} alkyl;

30 hver R^{2c} er uavhengig valgt fra gruppen som består av hydrogen, halogen, hydroksy, C_{1-6} alkoksy, C_{1-6} haloalkoksy, -CN, og $NR^{2a}R^{2b}$;

R^3 er valgt fra gruppen som består av fenyl og pyridyl, hver eventuelt substituert med 1-4 R^{3a} -grupper;

hver R^{3a} er uavhengig valgt fra gruppen som består av hydrogen, halogen, og C_{1-6} haloalkyl; og den senkede skriften n er et heltall fra 0 til 3.

3. Forbindelsen ifølge ett av kravene 1 til 2, hvori:

5 (a) R^1 er en heteroarylring som har fra 5 til 6 ringmedlemmer og fra 1 til 3 heteroatomer hver uavhengig valgt fra gruppen som består av N, O og S, eventuelt substituert med 1-4 grupper hver uavhengig valgt fra R^{1a} ;

hver R^{1a} er uavhengig valgt fra gruppen som består av hydrogen, C_{1-6} alkyl, C_{1-6} haloalkyl, og C_{1-6} alkoksy;

10 ring J er valgt fra gruppen som består av tetrahydrofuran, fenyl og pyridyl;

hver R^2 er uavhengig valgt fra gruppen som består av hydrogen, C_{1-6} alkyl, halogen, C_{1-6} haloalkyl, C_{1-6} alkoksy, C_{1-6} haloalkoksy, -CN, $NR^{2a}R^{2b}$, C_{3-8} sykloalkyl, og C_{3-8} heterosykloalkyl;

R^{2a} og R^{2b} er hver uavhengig valgt fra gruppen som består av hydrogen og 15 C_{1-6} alkyl;

R^3 er valgt fra gruppen som består av fenyl og pyridyl;

R^{3a} er F; og

den senkede skriften n er 0 eller 1; eller

(b) R^1 er en heteroarylring som har fra 5 til 6 ringmedlemmer og fra 1 til 3 20 heteroatomer hver uavhengig valgt fra gruppen som består av N, O og S, eventuelt substituert med 1-4 grupper hver uavhengig valgt fra R^{1a} ;

hver R^{1a} er uavhengig valgt fra gruppen som består av hydrogen, C_{1-6} alkyl, C_{1-6} haloalkyl, og C_{1-6} alkoksy;

ring J er valgt fra gruppen som består av fenyl og pyridyl;

25 hver R^2 er uavhengig valgt fra gruppen som består av hydrogen, halogen, C_{1-6} haloalkyl, CN og C_{5-6} heterosykloalkyl;

R^3 er valgt fra gruppen som består av fenyl og pyridyl; og

R^{3a} er F.

4. Forbindelsen ifølge ett av kravene 1 til 3, hvori R^1 er valgt fra gruppen som 30 består av

(a) pyrrol, pyrazol, imidazol, triazol, tetrazol, furan, oksazol, isoksazol, oksadiazol, tiofen, tiazol, isotiazol, tiadiazol, pyridin, pyrazin, pyrimidin og pyridazin;

(b) 2-pyrrol, 3-pyrrol, 3-pyrazol, 4-pyrazol, 5-pyrazol, 2-imidazol, 4-imidazol, 5-imidazol, 1,2,3-triazol-4-yl, 1,2,3-triazol-5-yl, 1,2,4-triazol-3-yl, 1,2,4-triazol-5-yl, 1,2,3,4-tetrazol-1-yl, 1,2,3,4-tetrazol-5-yl, 2-furan, 3-furan, 2-oksazol, 4-oksazol, 5-oksazol, 3-isoksazol, 4-isoksazol, 5-isoksazol, 1,2,4-oksadiazol-3-yl, 1,2,4-oksadiazol-5-yl, 1,2,5-oksadiazol-3-yl, 1,3,4-oksadiazol-2-yl, 2-tiofen, 3-tiofen, 2-tiazol, 4-tiazol, 5-tiazol, 3-isotiazol, 4-isotiazol, 5-isotiazol, 1,2,3-tiadiazol-4-yl, 1,2,3-tiadiazol-5-yl, 1,2,4-tiadiazol-3-yl, 1,2,4-tiadiazol-5-yl, 1,2,5-tiadiazol-3-yl, 1,3,4-tiadiazol-2-yl, 2-pyridin, 3-pyridin, 4-pyridin, pyrazin, 2-pyrimidin, 4-pyrimidin, 5-pyrimidin, 6-pyrimidin, 3-pyridazin, 4-pyridazin, 5-pyridazin, og 6-pyridazin;

10 (c) pyrazol, imidazol, triazol, furan, oksazol, oksadiazol, tiofen, tiazol, pyridin, pyrazin og pyrimidin; eller

(d) 1-pyrazol, 3-pyrazol, 4-pyrazol, 5-pyrazol, 2-imidazol, 4-imidazol, 5-imidazol, 1,2,3-triazol-4-yl, 1,2,3-triazol-5-yl, 1,2,4-triazol-3-yl, 1,2,4-triazol-5-yl, 2-furan, 3-furan, 2-oksazol, 4-oksazol, 5-oksazol, 1,2,4-oksadiazol-3-yl, 1,2,4-oksadiazol-5-yl, 1,2,5-oksadiazol-3-yl, 1,3,4-oksadiazol-2-yl, 2-tiofen, 3-tiofen, 2-tiazol, 4-tiazol, 5-tiazol, 2-pyridin, 3-pyridin, 4-pyridin, pyrazin, 2-pyrimidin, 4-pyrimidin, 5-pyrimidin og 6-pyrimidin.

5. Forbindelsen ifølge ett av kravene 1, 2 og 4, hvori hver R^{1a} er uavhengig valgt fra gruppen som består av hydrogen, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} alkoksy og C_{3-8} heterosykloalkyl.

6. Forbindelsen ifølge ett av kravene 1 til 5, hvori hver R^{1a} er uavhengig valgt fra gruppen som består av hydrogen, metyl, etyl, trifluormetyl og metoksy.

7. Forbindelsen ifølge ett av kravene 1, 2 og 4 til 6, hvori ring J er valgt fra gruppen som består av

25 (a) heterosykloalkyl, aryl og heteroaryl;

(b) aryl og heteroaryl; eller

(c) fenyl, pyridin, imidazol, pyrazol, triazol, tetrazol, tiadiazol, isotiazol, isoksazol, sykloheksyl, tetrahydrofuran og tetrahydro-2H-pyran.

8. Forbindelsen ifølge ett av kravene 1 til 7, hvori ring J er fenyl eller pyridyl.

30 9. Forbindelsen ifølge ett av kravene 1 og 4 til 8, hvori hver R^2 er uavhengig valgt fra gruppen som består av

(a) hydrogen, C_{1-6} alkyl, halogen, C_{1-6} haloalkyl, C_{1-6} alkoksy, C_{1-6} haloalkoksy, C_{1-6} alkyl- C_{1-6} alkoksy, -CN, $NR^{2a}R^{2b}$, $C(O)OR^{2a}$, $S(O)_2R^{2a}$, C_{3-8} sykloalkyl, eller C_3 -

heterosykloalkyl, hvori heterosykloalkylgruppen har 5-6 ringmedlemmer og 1 til 2 heteroatomer; eller

(b) hydrogen, metyl, etyl, propyl, isopropyl, F, Cl, $-\text{CF}_3$, CH_2OMe , OMe, OCHF_2 , $-\text{CN}$, $-\text{NMe}_2$, $-\text{C}(\text{O})\text{OH}$, $-\text{C}(\text{O})\text{NMe}_2$, $-\text{S}(\text{O})_2\text{Me}$, pyrrolidin, piperidin eller morfolin.

10. Forbindelsen ifølge ett av kravene 1 til 9, hvori R^3 er 4-F-fenyl.

11. Forbindelsen ifølge krav 1, hvori forbindelsen er valgt fra gruppen som består av:

(R)-(6-((6-klorpyridin-3-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,

(R)-(6-((6-klorpyridin-3-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,

(R)-(1-(4-fluorfenyl)-6-((4-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,

(R)-(1-(4-fluorfenyl)-6-((4-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(1-metyl-1H-imidazol-2-yl)metanon,

(R)-(1-(4-fluorfenyl)-6-((4-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-3-yl)metanon,

(R)-(1-(4-fluorfenyl)-6-((4-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,

(R)-(1-(4-fluorfenyl)-6-((4-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(5-metyl-1,3,4-oksadiazol-2-yl)metanon,

(R)-(1-(4-fluorfenyl)-6-((4-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(oksazol-4-yl)metanon,

(R)-(1-(4-fluorfenyl)-6-((4-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(oksazol-2-yl)metanon,

(R)-(1-(4-fluorfenyl)-6-((4-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(furan-2-yl)metanon,

(R)-(1-(4-fluorfenyl)-6-((4-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(thiofen-2-yl)metanon,

(R)-(1-(4-fluorfenyl)-6-(m-tolylsulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(oksazol-2-yl)metanon,

- (R)-(1-(4-fluorfenyl)-6-(m-tolylsulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyrimidin-2-yl)metanon,
- (R)-(6-((3,5-difluorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metoksypyridin-2-yl)metanon,
- 5 (R)-(4-etylpyridin-2-yl)(1-(4-fluorfenyl)-6-((3,4,5-trifluorfenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((3,4,5-trifluorfenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metoksypyridin-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((4-fluorfenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- 10 (R)-(6-((3-fluorbenzyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,
- ((4aR)-1-(4-fluorfenyl)-6-(((R/S)-tetrahydrofuran-2-yl)metyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,
- 15 (R)-(1-(4-fluorfenyl)-6-(o-tolylsulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-(6-((4-etylfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-(m-tolylsulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- 20 (R)-(6-((3-klorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((3-metoksifyenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- 25 (R)-(6-((4-klor-3-fluorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((4-metoksifyenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-(6-((3-fluor-4-metylfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- 30 (R)-(1-(4-fluorfenyl)-6-(fenylsulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,

- (R)-(1-(4-fluorfenyl)-6-((2-fluorfenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((1-metyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- 5 (R)-(1-(4-fluorfenyl)-6-((6-(trifluormetyl)pyridin-3-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-tosyl-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-(6-((4-fluor-3-(trifluormetyl)fenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- 10 (R)-4-((1-(4-fluorfenyl)-4a-pikolinoyl-4a,5,7,8-tetrahydro-1H-pyrazolo[3,4-g]isokinolin-6(4H)-yl)sulfonyl)benzonitril,
- (R)-(1-(4-fluorfenyl)-6-((6-metoksypyridin-3-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- 15 (R)-(1-(4-fluorfenyl)-6-((tetrahydro-2H-pyran-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-(6-(sykloheksylsulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-(6-((etyl-1H-pyrazol-5-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,
- 20 (R)-(6-((3,5-dimetyl-1H-pyrazol-4-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,
- 25 (R)-(6-((1H-imidazol-4-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((6-morfolinopyridin-3-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((6-(pyrrolidin-1-yl)pyridin-3-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,
- 30 (R)-(1-(4-fluorfenyl)-6-((4-fluorfenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,

- (R)-(1-(4-fluorfenyl)-6-((3-fluorfenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,
- (R)-4-(((1-(4-fluorfenyl)-4a-(tiazol-2-karbonyl)-4a,5,7,8-tetrahydro-1H-pyrazolo[3,4-g]isokinolin-6(4H)-yl)sulfonyl)metyl)benzonitril,
- 5 (R)-(1-(4-fluorfenyl)-6-((3-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((4-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(1-metyl-1H-1,2,4-triazol-5-yl)metanon,
- 10 (R)-(1-(4-fluorfenyl)-6-((4-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyrazin-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((5-fluorpyridin-3-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((3-fluorfenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- 15 (R)-(1-(4-fluorfenyl)-6-((4-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(5-metoksypyridin-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((4-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-5-yl)metanon,
- 20 (R)-(1-(4-fluorfenyl)-6-((5-fluorpyridin-3-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((4-(pyrrolidin-1-yl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((3-(pyrrolidin-1-yl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,
- 25 (R)-(1-(4-fluorfenyl)-6-((5-(piperidin-1-yl)pyridin-3-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((5-(pyrrolidin-1-yl)pyridin-3-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,
- 30 (R)-(1-(4-fluorfenyl)-6-((6-(pyrrolidin-1-yl)pyridin-3-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- ((R)-1-(4-fluorfenyl)-6-((6-((R)-3-fluorpyrrolidin-1-yl)pyridin-3-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,

- (R)-(1-(4-fluorfenyl)-6-((4-(pyrrolidin-1-yl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((5-(piperidin-1-yl)pyridin-3-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- 5 (R)-(1-(4-fluorfenyl)-6-((5-(pyrrolidin-1-yl)pyridin-3-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((4-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-4-yl)metanon,
- (R)-(6-((4-klorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- 10 (R)-(1-(4-fluorfenyl)-6-((4-metoksy-3-metylfenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-(6-((3-klor-4-metoksyfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- 15 (R)-(6-((3-fluor-4-metoksyfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-(6-((2-fluor-4-metylfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-(m-tolylsulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-4-yl)metanon,
- 20 (R)-3-((1-(4-fluorfenyl)-4a-pikolinoyl-4a,5,7,8-tetrahydro-1H-pyrazolo[3,4-g]isokinolin-6(4H)-yl)sulfonyl)benzonitril,
- (R)-(6-((4-(difluormetoksy)fenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- 25 (R)-(1-(4-fluorfenyl)-6-((3-(trifluormetoksy)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-(6-((3,5-difluorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-tosyl-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-4-yl)metanon,
- 30 (R)-(6-((3-(difluormetoksy)fenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,

- (R)-(6-((3,4-dimetylfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-(6-((3,5-dimetylfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- 5 (R)-(1-(4-fluorfenyl)-6-((6-metylpyridin-2-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-(6-((3,4-difluorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((3,4,5-trifluorfenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-10 1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-(6-((3-klor-4-fluorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-3-((1-(4-fluorfenyl)-4a-(4-metylpikolinoyl)-4a,5,7,8-tetrahydro-1H-pyrazolo[3,4-g]isokinolin-6(4H)-yl)sulfonyl)benzonitril,
- 15 (R)-(1-(4-fluorfenyl)-6-((1-metyl-1-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metylpyridin-2-yl)metanon,
- (R)-(6-((3,4-difluorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metylpyridin-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((1-metyl-1H-imidazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metylpyridin-2-yl)metanon,
- 20 (R)-(6-((3,5-difluorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metylpyridin-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((3,4,5-trifluorfenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metylpyridin-2-yl)metanon,
- 25 (R)-(1-(4-fluorfenyl)-6-((3-(metylsulfonyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-3-((1-(4-fluorfenyl)-4a-pikolinoyl-4a,5,7,8-tetrahydro-1H-pyrazolo[3,4-g]isokinolin-6(4H)-yl)sulfonyl)benzosyre,
- (R)-(1-(4-fluorfenyl)-6-((3-(metoksymetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- 30 (R)-(1-(4-fluorfenyl)-6-((4-metyl-3,4-dihydro-2H-pyrido[3,2-b][1,4]oksazin-7-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,

- (R)-(1-(4-fluorfenyl)-6-((2,3,4-trifluorfenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((6-(trifluormetyl)pyridin-2-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- 5 (R)-(1-(4-fluorfenyl)-6-((6-(trifluormetyl)pyridin-2-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metylpyridin-2-yl)metanon,
- (R)-(6-((3,4-diklorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((3-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metylpyridin-2-yl)metanon,
- 10 (R)-(6-((1-etyl-1H-pyrazol-4-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metylpyridin-2-yl)metanon,
- (R)-(6-((1,5-dimetyl-1H-pyrazol-4-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metylpyridin-2-yl)metanon,
- 15 (R)-(1-(4-fluorfenyl)-6-((1-metyl-1H-pyrazol-5-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metylpyridin-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((1-metyl-1H-pyrazol-3-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metylpyridin-2-yl)metanon,
- (R)-(6-((4-fluor-3-metylfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metylpyridin-2-yl)metanon,
- 20 (R)-(1-(4-fluorfenyl)-6-((4-metyl-3,4-dihydro-2H-pyrido[3,2-b][1,4]oksazin-7-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metylpyridin-2-yl)metanon,
- (R)-(6-((2,3-dihydrobenzofuran-5-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metylpyridin-2-yl)metanon,
- 25 (R)-5-((1-(4-fluorfenyl)-4a-(4-metylpikolinoyl)-4a,5,7,8-tetrahydro-1H-pyrazolo[3,4-g]isokinolin-6(4H)-yl)sulfonyl)-1-metylindolin-2-on,
- (R)-(1-(4-fluorfenyl)-6-((3-(metylsulfonyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metylpyridin-2-yl)metanon,
- 30 (R)-(6-((1,3-dimetyl-1H-pyrazol-4-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metylpyridin-2-yl)metanon,

- (R)-(6-((2,3-dihydrobenzo[b][1,4]dioksin-6-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metylpyridin-2-yl)metanon,
- (R)-(6-((3-fluor-4-(trifluormetyl)fenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metylpyridin-2-yl)metanon,
- (R)-(6-((3-fluor-4-(trifluormetyl)fenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-3-((4a-(4-etyl pikolinoyl)-1-(4-fluorfenyl)-4a,5,7,8-tetrahydro-1H-pyrazolo[3,4-g]isokinolin-6(4H)-yl)sulfonyl)benzonitril,
- (R)-(4-etylpyridin-2-yl)(1-(4-fluorfenyl)-6-((6-(trifluormetyl)pyridin-2-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)metanon,
- (R)-3-((1-(4-fluorfenyl)-4a-(4-metyl pikolinoyl)-4a,5,7,8-tetrahydro-1H-pyrazolo[3,4-g]isokinolin-6(4H)-yl)sulfonyl)benzosyre,
- (R)-(6-((3,5-dimetyl isoksazol-4-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metylpyridin-2-yl)metanon,
- (R)-(6-((1-etyl-1H-pyrazol-4-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-(1-fenyl-6-((3-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-(6-((1,3-dimetyl-1H-pyrazol-5-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metylpyridin-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((2-(trifluormetyl)pyridin-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metylpyridin-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((4-(trifluormetyl)pyridin-2-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metylpyridin-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((5-metyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metylpyridin-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((2-(trifluormetyl)pyridin-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-(6-((4-klor-3-(trifluormetyl)fenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-(6-((3-klor-4-metyl fenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,

(R)-(6-((3,4-difluorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(2-(pyrrolidin-1-yl)pyridin-4-yl)metanon,

(R)-(1-(4-fluorfenyl)-6-((1-metyl-1H-pyrazol-3-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,

(R)-(1-(4-fluorfenyl)-6-((1-metyl-1H-pyrazol-3-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,

(R)-(1-(4-fluorfenyl)-6-((5-metyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,

(R)-3-((1-(4-fluorfenyl)-4a-(4-(trifluormetyl)pikolinoyl)-4a,5,7,8-tetrahydro-1H-pyrazolo[3,4-g]isokinolin-6(4H)-yl)sulfonyl)benzonitril,

(R)-(1-(4-fluorfenyl)-6-((1-metyl-1H-pyrazol-5-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,

(R)-(6-((1,5-dimetyl-1H-pyrazol-4-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,

(R)-(6-((1H-pyrazol-4-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,

(R)-(1-(4-fluorfenyl)-6-((1-metyl-3-(trifluormetyl)-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,

(R)-(1-(4-fluorfenyl)-6-((3,4,5-trifluorfenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,

(R)-(1-(4-klorfenyl)-6-((1-metyl-1H-pyrazol-3-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,

(R)-(6-((1H-pyrazol-4-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,

(R)-(6-((1-metyl-1H-pyrazol-3-yl)sulfonyl)-1-(4-(trifluormetyl)fenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,

(R)-(6-((3,4-difluorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-4-yl)metanon,

(R)-(6-((1,2-dimetyl-1H-imidazol-4-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,

(R)-(6-((1,2-dimetyl-1H-imidazol-5-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,

(R)-(1-(4-fluorfenyl)-6-((1-metyl-1H-imidazol-2-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,

(R)-(6-((1-etyl-1H-imidazol-4-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,

(R)-(6-((1-etyl-1H-pyrazol-4-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-4-yl)metanon,

(R)-(1-(4-fluorfenyl)-6-((1-propyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,

(R)-(1-(4-fluorfenyl)-6-((1-(2-metoksyetyl)-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,

(R)-(6-((3,4-diklorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(1-metyl-1H-pyrazol-4-yl)metanon,

(R)-(1-(4-fluorfenyl)-6-((1-isopropyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,

(R)-(1-(4-fluorfenyl)-6-((2-metyl-2H-1,2,3-triazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,

(R)-(1-(4-fluorfenyl)-6-((1-metyl-1H-1,2,3-triazol-5-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,

(R)-(1-(4-fluorfenyl)-6-((1-metyl-1H-1,2,3-triazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,

(R)-(6-((2-etyl-2H-1,2,3-triazol-4-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,

(R)-(6-((1-ethyl-1H-1,2,3-triazol-5-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,

(R)-(6-((1-ethyl-1H-1,2,3-triazol-4-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,

5 (R)-(6-((2-ethyl-2H-1,2,3-triazol-4-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,

(R)-(6-((1-ethyl-1H-1,2,3-triazol-5-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,

10 (R)-(6-((1-ethyl-1H-1,2,3-triazol-4-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,

(R)-(1-(4-fluorfenyl)-6-((2-propyl-2H-1,2,3-triazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,

15 (R)-(1-(4-fluorfenyl)-6-((1-propyl-1H-1,2,3-triazol-5-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,

(R)-(1-(4-fluorfenyl)-6-((1-propyl-1H-1,2,3-triazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,

20 (R)-(1-(4-fluorfenyl)-6-((2-propyl-2H-1,2,3-triazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-4-yl)metanon,

(R)-(1-(4-fluorfenyl)-6-((1-propyl-1H-1,2,3-triazol-5-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-4-yl)metanon,

25 (R)-(1-(4-fluorfenyl)-6-((1-propyl-1H-1,2,3-triazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-4-yl)metanon,

(R)-(1-(4-fluorfenyl)-6-((2-isopropyl-2H-1,2,3-triazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,

(R)-(1-(4-fluorfenyl)-6-((1-isopropyl-1H-1,2,3-triazol-5-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,

30 (R)-(1-(4-fluorfenyl)-6-((1-isopropyl-1H-1,2,3-triazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,

(R)-(6-((1-ethyl-1H-pyrazol-5-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-4-yl)metanon,

- (R)-(1-(4-fluorfenyl)-6-((1-propyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((1-metyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-4-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((1-propyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-4-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((3-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-(m-tolylsulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((3-metoksyfenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,
- (R)-(6-((3-fluor-4-metylfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-(fenylsulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,
- (R)-(6-((3-klorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-(m-tolylsulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(5-metylpyridin-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-(m-tolylsulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metylpyridin-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-(m-tolylsulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(6-metylpyridin-2-yl)metanon,
- (R)-(6-((4-fluor-3-(trifluormetyl)fenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((3,4,5-trifluorfenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,
- (R)-(6-((3-fluor-4-(trifluormetyl)fenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((3-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(5-metyltiazol-2-yl)metanon,

- (R)-(1-(4-fluorfenyl)-6-((3-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metyltiazol-2-yl)metanon,
- (R)-(6-((3,4-diklorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,
- 5 (R)-(6-((3,4-diklorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(5-metyltiazol-2-yl)metanon,
- (R)-(6-((3,4-difluorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,
- (R)-(6-((3,4-difluorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-10 1H-pyrazolo[3,4-g]isokinolin-4a-yl)(5-metyltiazol-2-yl)metanon,
- (R)-(6-((4-klor-3-fluorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(5-metyltiazol-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((1-metyl-1H-pyrazol-3-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(5-metyltiazol-2-yl)metanon,
- 15 (R)-(1-(4-fluorfenyl)-6-((1-metyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(5-metyltiazol-2-yl)metanon,
- (R)-(6-((1,3-dimetyl-1H-pyrazol-5-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(5-metyltiazol-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((1-metyl-1H-pyrazol-5-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(5-metyltiazol-2-yl)metanon,
- 20 (R)-(6-((1-etyl-1H-pyrazol-5-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,
- (R)-(6-((1-etyl-1H-pyrazol-4-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,
- 25 (R)-(1-(4-fluorfenyl)-6-((1-propyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-tosyl-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(1-metyl-1H-imidazol-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-(m-tolylsulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo [3,4-g]isokinolin-4a-yl)(1-metyl-1H-imidazol-2-yl)metanon ,
- 30 (R)-3-((1-(4-fluorfenyl)-4a-pikolinoyl-4a,5,7,8-tetrahydro-1H-pyrazolo[3,4-g]isokinolin-6(4H)-yl)sulfonyl)-N,N-dimetylbenzamid,

(R)-(6-((1-etyl-1H-pyrazol-4-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,

(R)-pyridin-2-yl(1-(pyridin-3-yl)-6-((3-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)metanon,

(R)-(6-((3,4-diklorfenyl)sulfonyl)-1-fenyl-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,

(R)-(6-((3,4-diklorfenyl)sulfonyl)-1-(3,4-difluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,

(R)-(6-((3,5-difluor-4-metoksyfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,

(R)-(6-((6-(dimetylamino)pyridin-3-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,

(R)-5-((1-(4-fluorfenyl)-4a-pikolinoyl-4a,5,7,8-tetrahydro-1H-pyrazolo[3,4-g]isokinolin-6(4H)-yl)sulfonyl)-1-metylpyridin-2(1H)-on,

(R)-(1-(4-fluorfenyl)-6-((1-metyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon, og

(R)-(6-((3,4-diklorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-4-yl)metanon, eller salter derav.

12. Forbindelsen ifølge krav 1, hvori forbindelsen er valgt fra gruppen som består av:

(R)-(1-(4-fluorfenyl)-6-((4-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,

(R)-(1-(4-fluorfenyl)-6-((4-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,

(R)-(6-((3,4-difluorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,

(R)-(6-((3,4-diklorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,

(R)-(1-(4-fluorfenyl)-6-((1-metyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,

(R)-(6-((3,4-diklorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,

(R)-(6-((3,4-diklorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(5-metyltiazol-2-yl)metanon,

5 (R)-(6-((3-fluor-4-(trifluormetyl)fenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon ,

(R)-(1-(4-fluorfenyl)-6-((1-metyl-1H-pyrazol-3-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,

10 (R)-(1-(4-fluorfenyl)-6-((1-metyl-1H-pyrazol-5-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,

(R)-(6-((1-etyl-1H-pyrazol-5-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-

15 yl)metanon, eller

(R)-(6-((3,4-diklorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-4-yl)metanon.

13. Farmasøytisk sammensetning som omfatter en forbindelse ifølge ett av kravene 1 til 12 og en farmasøytisk akseptabel eksipiens, som eventuelt ytterligere
20 omfatter et antiinflammatorisk glukokortikosteroid.

14. Forbindelse ifølge ett av kravene 1 til 12 for anvendelse i en fremgangsmåte for behandling av inflammatoriske sykdommer, autoimmune sykdommer og/eller kreft, hvori fremgangsmåten omfatter modulering av en glukokortikoidreseptor som omfatter å bringe glukokortikoidreseptoren i kontakt
25 med forbindelsen.

15. Forbindelse ifølge ett av kravene 1 til 12 for anvendelse i en fremgangsmåte for behandling av en forstyrrelse valgt fra gruppen som består av fedme, diabetes, kardiovaskulær sykdom, hypertensjon, syndrom X, depresjon, angst, glaukom, humant immundefektvirus (HIV) eller ervervet
30 immundefektssyndrom (AIDS), nevrodegenerasjon, Alzheimers sykdom, Parkinsons sykdom, kognisjonsforbedring, Cushings syndrom, Addisons sykdom, osteoporose, skjørhet, muskelsvikt, inflammatoriske sykdommer, slitasjegikt, revmatoid artritt, astma og rhinitt, adrenalfunksjonsrelaterte plager, virusinfeksjon,

immundefekt, immunmodulering, autoimmune sykdommer, allergier, sårheling, tvangsmessig adferd, multilegemiddelmotstand, avhengighet, psykose, anoreksi, kakeksi, posttraumatisk stressyndrom, postkirurgisk beinfraktur, medisinsk katabolisme, større psykotisk depresjon, mild kognitiv svekkelse, psykose, 5 demens, hyperglykemi, stressforstyrrelser, antipsykotisk induisert vektøkning, delirium, kognitiv forringelse hos individer med Downs syndrom, psykose forbundet med interferon-alfa-behandling, kronisk smerte, smerte assosiert med gastroøsofageal reflukssykdom, postpartumpsykose, postpartumdepresjon, nevrologiske forstyrrelser hos premature spedbarn og migrenehodepine; gjennom 10 antagonisering av en glukokortikoidreseptor, idet fremgangsmåten omfatter å administrere en terapeutisk effektiv mengde av forbindelsen til et individ som har behov for det, for derved å behandle forstyrrelsen.